• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?

作者信息

Xi Yongzhi

机构信息

Department of Immunology and National Center for Biomedicine Analysis, Fifth Medical Center of Chinese PLA General Hospital, No. 8, Dongda Ave, Fengtai District, 100071, Beijing, P.R. China.

出版信息

Signal Transduct Target Ther. 2020 Sep 15;5(1):203. doi: 10.1038/s41392-020-00310-8.

DOI:10.1038/s41392-020-00310-8
PMID:32934211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7490573/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0f/7492415/c58b82a104be/41392_2020_310_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0f/7492415/c58b82a104be/41392_2020_310_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0f/7492415/c58b82a104be/41392_2020_310_Fig1_HTML.jpg

相似文献

1
Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?新冠康复者血浆疗法：一种久经考验的古老策略？
Signal Transduct Target Ther. 2020 Sep 15;5(1):203. doi: 10.1038/s41392-020-00310-8.
2
Storm of soluble immune checkpoints associated with disease severity of COVID-19.与新型冠状病毒肺炎疾病严重程度相关的可溶性免疫检查点风暴
Signal Transduct Target Ther. 2020 Sep 7;5(1):192. doi: 10.1038/s41392-020-00308-2.
3
Antibody-dependent enhancement and COVID-19: Moving toward acquittal.抗体依赖性增强作用与 COVID-19：走向无罪。
Clin Immunol. 2020 Aug;217:108496. doi: 10.1016/j.clim.2020.108496. Epub 2020 Jun 8.
4
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
5
Management of COVID-19 Virus Infection by Convalescent Plasma.恢复期血浆治疗新型冠状病毒肺炎病毒感染
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):3-6. doi: 10.18502/ijaai.v19i(s1.r1).2847.
6
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
7
Challenges of Convalescent Plasma Therapy on COVID-19.恢复期血浆疗法治疗新冠病毒肺炎面临的挑战
J Clin Virol. 2020 Jun;127:104358. doi: 10.1016/j.jcv.2020.104358. Epub 2020 Apr 10.
8
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.用恢复期血浆治疗 COVID-19：从过去的冠状病毒爆发中吸取的教训。
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
9
Expansion of atypical memory B cells is a prominent feature of COVID-19.非典型记忆B细胞的扩增是新冠病毒病的一个显著特征。
Cell Mol Immunol. 2020 Oct;17(10):1101-1103. doi: 10.1038/s41423-020-00542-2. Epub 2020 Sep 2.
10
Convalescent plasma - Is it useful for treating SARS Co-V2 infection?恢复期血浆——对治疗新冠病毒感染有用吗？
Indian J Med Microbiol. 2020 Jul-Dec;38(3 & 4):252-260. doi: 10.4103/ijmm.IJMM_20_358.

引用本文的文献

1
Antibody-dependent enhancement of coronaviruses.冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
2
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.不同COVID-19严重程度等级的肯尼亚SARS-CoV-2感染者中自然诱导的抗SARS-CoV-2抗体结合水平、中和抗体水平及效力的动力学：一项观察性研究
Wellcome Open Res. 2024 Dec 2;8:350. doi: 10.12688/wellcomeopenres.19414.2. eCollection 2023.
3
Passive antibody therapy in emerging infectious diseases.
新发传染病中的被动抗体疗法。
Front Med. 2023 Dec;17(6):1117-1134. doi: 10.1007/s11684-023-1021-y. Epub 2023 Dec 2.
4
Microbead-based extracorporeal immuno-affinity virus capture: a feasibility study to address the SARS-CoV-2 pandemic.基于微珠的体外免疫亲和病毒捕获：应对 SARS-CoV-2 大流行的可行性研究。
Mikrochim Acta. 2023 Feb 18;190(3):95. doi: 10.1007/s00604-023-05671-9.
5
Acute Cerebellitis and Myeloradiculitis Associated With SARS-CoV-2 Infection in Common Variable Immunodeficiency-A Case Report.普通可变免疫缺陷中与SARS-CoV-2感染相关的急性小脑炎和脊髓神经根炎——病例报告
Neurohospitalist. 2022 Apr;12(2):361-365. doi: 10.1177/19418744211050215. Epub 2021 Dec 31.
6
Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers.评估BNT162b2疫苗接种后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体及其与SARS-CoV-2 IgG抗S1、抗受体结合域（RBD）和抗S2血清学滴度的相关性
Diagnostics (Basel). 2022 Jan 15;12(1):205. doi: 10.3390/diagnostics12010205.
7
Stem cells or their exosomes: which is preferred in COVID-19 treatment?干细胞或其外泌体：在 COVID-19 治疗中哪个更优？
Biotechnol Lett. 2022 Feb;44(2):159-177. doi: 10.1007/s10529-021-03209-8. Epub 2022 Jan 19.
8
Immunotherapy Summary for Cytokine Storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的免疫治疗概述
Front Pharmacol. 2021 Sep 17;12:731847. doi: 10.3389/fphar.2021.731847. eCollection 2021.
9
The Immunopathobiology of SARS-CoV-2 Infection.严重急性呼吸综合征冠状病毒 2 型感染的免疫病理生物学。
FEMS Microbiol Rev. 2021 Nov 23;45(6). doi: 10.1093/femsre/fuab035.
10
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.影响COVID-19患者发病机制的多种免疫因素：关于病毒传播、对抗细胞因子风暴和炎症反应的免疫治疗选择的综述
Pathogens. 2021 May 7;10(5):565. doi: 10.3390/pathogens10050565.